George A. Samuel III - 07 Mar 2024 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LCTX	Employee Stock Option (Right to Buy)	Award	$0	+650,000		$0.000000	650,000	07 Mar 2024	Common Shares	650,000	$1.13	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	One quarter of the options shall vest on March 7, 2025, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.